JH-X-119-01

N/A

Report date: 2022/07/01 15:29:28
NME

Base Information

Drug NameJH-X-119-01
Drug Alias NameJH-X-119-01
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-1 receptor-associated kinase 1 antagonists
TargetsInterleukin-1 receptor-associated kinase 1
Therapy Area/IndicationsWaldenstrom MacroglobulinemiaLymphoma, Large B-Cell, Diffuse
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesDana-Farber Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer Institute
Inactive CompaniesN/A
Active IndicationsWaldenstrom MacroglobulinemiaLymphoma, Large B-Cell, Diffuse
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A